文献速递眼底病与葡萄膜炎

氟轻松醋酸酯植入剂对非感染性中间、后段或全葡萄膜炎复发率的影响:三年结果

Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results.
PubMed 文献 · Ophthalmology · 2020-04-17

结果显示,FAi组葡萄膜炎累积复发率(65.5% vs 97.6%,P<0.001)显著低于假手术组,首次复发时间显著延长,复发次数更少,辅助治疗需求更少;白内障手术需求更高,眼压相关手术比例较低。

要点

  • FAi显著降低36个月累积复发率(65.5% vs 97.6%,P<0.001)并延长首次复发时间。
  • FAi组每眼平均复发次数更低(1.7 vs 5.3,P<0.001),辅助治疗需求更少(57.5% vs 97.6%)。
  • FAi组白内障手术需求更高(73.8% vs 23.8%),需权衡获益与不良反应。

核心结论

  • 0.2 μg/日氟轻松醋酸酯植入剂可显著降低非感染性后段葡萄膜炎的复发率、延长无复发时间并减少辅助治疗,安全性可接受。

研究设计与样本

  • 3期、前瞻性、双盲、多中心研究(NCT01694186),纳入≥18岁、非感染性后段葡萄膜炎≥1年且≥2次复发需系统激素、免疫抑制或眼内激素治疗的成人。

主要发现

  • 36个月累积复发率FAi组65.5%、假手术组97.6%(P<0.001),首次复发中位时间分别为657.0天和70.5天(P<0.001)。
  • 每眼平均复发次数FAi组1.7次、假手术组5.3次(P<0.001)。
  • 36个月时BCVA较基线增加≥15字母的比例FAi组33.3%、假手术组14.7%;研究者判定的黄斑水肿比例FAi组13.0%、假手术组27.3%。
  • 需辅助治疗者FAi组57.5%、假手术组97.6%;36个月眼压均值FAi组14.5±5.1、假手术组14.8±5.3。
  • 接受降眼压手术比例FAi组5.7%、假手术组11.9%;36个月内白内障手术比例FAi组73.8%、假手术组23.8%。

关键数值与推荐

  • 主要终点为FAi组与假手术组复发患者比例的差异;次要终点包括首次复发时间、复发次数、BCVA变化、黄斑水肿消退及辅助治疗次数。
  • 36个月累积复发率65.5% vs 97.6%(P<0.001);首次复发中位时间657.0天 vs 70.5天(P<0.001);每眼平均复发次数1.7 vs 5.3(P<0.001)。
  • BCVA增加≥15字母比例33.3% vs 14.7%;黄斑水肿比例13.0% vs 27.3%;辅助治疗比例57.5% vs 97.6%。
  • 36个月眼压14.5±5.1 vs 14.8±5.3;降眼压手术5.7% vs 11.9%;白内障手术73.8% vs 23.8%。

临床怎么用

  • 对于反复复发、需系统激素或免疫抑制治疗的非感染性后段葡萄膜炎成人,FAi可显著减少复发和辅助治疗需求。
  • 植入前应评估白内障风险,FAi组36个月白内障手术比例明显更高(73.8% vs 23.8%),需与患者充分沟通。
  • 眼压方面FAi组与假手术组均值相近,降眼压手术比例较低(5.7% vs 11.9%),但仍需规律监测眼压。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the 36-month efficacy and safety of a 0.2 μg/day fluocinolone acetonide insert (FAi) to treat noninfectious uveitis of the posterior segment (NIU-PS). DESIGN: Phase 3, prospective, double-masked, multicenter study (clinicaltrials.gov, NCT01694186). PARTICIPANTS: Adults (≥18 years old) with a diagnosis of NIU-PS in ≥1 eye for ≥1 year and ≥2 recurrences of uveitis requiring systemic corticosteroid, immunosuppressive treatment, or intraocular corticosteroids. METHODS: Participants were randomized 2:1 to FAi or sham (injection plus standard of care) treatment. MAIN OUTCOME MEASURES: The primary outcome was the difference between the proportion of FAi-treated and sham-treated patients who had a uveitis recurrence. Secondary outcomes included time to first recurrence, number of recurrences, best-corrected visual acuity (BCVA) change from baseline, resolution of macular edema, and number of adjunctive treatments. RESULTS: One hundred twenty-nine participants (n = 87 FAi-treated; n = 42 sham-treated) were enrolled. Over 36 months of treatment, cumulative uveitis recurrences were significantly reduced with FAi compared with sham (65.5% vs. 97.6%, respectively; P < 0.001); time to first recurrence was commensurately longer (median 657.0 and 70.5 days, respectively; P < 0.001). The number of recurrences per eye was significantly lower in the FAi-treated compared with the sham-treated group (mean 1.7 vs. 5.3, respectively, P < 0.001). At 36 months, more FAi-treated eyes had a ≥15-letter increase in BCVA from baseline and fewer FAi-treated eyes had investigator-determined macular edema at month 36 compared with sham-treated eyes (33.3% vs. 14.7% and 13.0% vs. 27.3% for BCVA and macular edema, respectively). Fewer FAi compared with sham-treated participants required adjunctive treatments (57.5% vs. 97.6%, respectively). Intraocular pressure (IOP) was similar for both study groups at month 36 (mean ± standard deviation 14.5±5.1 and 14.8±5.3, respectively), and approximately half as many eyes in the FAi-treated group when compared with the sham-treated group underwent IOP-lowering surgery (5.7% vs. 11.9%). Cataract surgery was required more frequently over 36 months in the FAi-treated compared with the sham-treated group (73.8% vs. 23.8% of eyes, respectively). CONCLUSIONS: Fluocinolone acetonide insert-treated eyes had significantly reduced uveitis recurrence rates throughout the study duration, significantly increased recurrence-free durations, fewer recurrence episodes among those with recurrences, less adjunctive therapy, and an acceptable side-effect profile compared with sham-treated eyes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Jaffe GJ, Pavesio CE. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results. Ophthalmology. 2020. PMID: 32624244. doi:10.1016/j.ophtha.2020.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。